Danish Pharmacovigilance Update, 21 March 2013

In this issue of Danish Pharmacovigilance Update:

• Depressive and suicidal thoughts following discontinuation of varenicline (Champix®) (front page)
• Risk of femoral fracture during treatment with Prolia® (denosumab) (p 2)
• The European Medicines Agency (EMA) is reviewing benefits and risks of the nicotinic acid analogue acipimox (Olbetam®) for the treatment of elevated cholesterol levels (p 3)
• Nulojix® (belatacept) and increased incidence of acute graft rejection in certain specific cases (p 4)
• Risks associated with off-label use of NeuroBloc® (botulinum toxin type B) (p 5)
• Childhood vaccinations and suspected adverse reactions in the third and fourth quarter of 2012 (pp 6-10)